摘要
目的探究阿奇霉素治疗支气管哮喘的临床疗效及安全性评价。方法选择本院2016年1月~2017年1月共100例支气管哮喘患者,采取随机的方式,分为对照组与观察组,对照组采取常规治疗,观察组采取阿奇霉素治疗,对比两组患者临床症状缓解时间、不良反应发生率。结果观察组支气管哮喘患者肺哮鸣音消失时间(3.62±1.02)d,咳嗽消失时间(4.33±1.23)d,呼吸困难改善时间(4.05±1.25)d,均优于对照组(P<0.05)。观察组患者不良反应发生率2.00%,明显低于对照组18.00%,P<0.05。结论采用阿奇霉素治疗支气管哮喘患者,且安全性较高,有效改善了患者临床症状,值得研究。
Objective To investigate the clinical efficacy and safety evaluation of azithromycin on bronchial asthma .Methods A total of 100 patients with bronchial asthma from January 2016 to January 2017 were randomized into the control group and observation group,the control group received conventional treatment, and the observation group was treated with azithromycin, the remission time of the clinical symptoms and the incidence of adverse reactions were compared . Results In observation group the time of pulmonary wheezing in patients with bronchial asthma was （3. 62± 1. 0 2 ）d ,the time of cough disappearance was （4. 33± 1. 23 ）d ,the time 0 dyspnea improvement was（4. 05± 1. 25 ）d ,which were better than the control group（P〈0 . 05）. The incidence of adverse reactions in the observation group 2% was significantly less than in the control group 18%（P〈0. 05）. Conclusion Azithromycin was used in patient with bronchial asthma, which can safely and effectively improve the clinical symptoms , worthy of study.
出处
《临床研究》
2018年第1期51-52,共2页
Clinical Research
